Los Angeles Hematology-Oncology Medical Group
Los Angeles Hematology-Oncology Medical Group was paid $13.97M by Medicaid between Jan 2018 and Dec 2024, across 69 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 18% of everything it billed.
33Billing provider infoLOS ANGELES HEMATOLOGY-ONCOLOGY MEDICAL GROUP
LOS ANGELES, CA 90017
LOS ANGELES, CA 90017
33aNPI1457409674assigned 01/05/2007
33bProvider typeSpecialist
28Total paid$13.97M
24GClaims452,383
24DCodes billed69
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Specialist providers in California
Rank by total paid#12 of 1,230
Median peer was paid$51K
This provider vs. median272×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 52,202 | $2.10M | |
| 2019 | 58,295 | $2.43M | |
| 2020 | 51,585 | $2.05M | |
| 2021 | 55,914 | $1.84M | |
| 2022 | 57,744 | $1.28M | |
| 2023 | 88,213 | $1.84M | |
| 2024incomplete | 88,430 | $2.44M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 18% | 92,933 | 72,445 | $2.45M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.6% | 49,829 | 42,234 | $1.06M |
| 96367 | 7.1% | 26,204 | 16,486 | $990K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 5.8% | 25,788 | 16,569 | $810K |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 5.8% | 6,897 | 1,825 | $807K |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | 5.6% | 262 | 175 | $781K |
| J9271 | Injection, pembrolizumab, 1 mg | 5.0% | 235 | 179 | $701K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 3.6% | 24,529 | 14,695 | $503K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.3% | 30,975 | 15,812 | $461K |
| 99233 | Hospital visit by a doctor, follow-up day (complex)Prolong inpt eval add15 m | 3.2% | 19,542 | 5,348 | $444K |
| J2469 | Injection, palonosetron hcl, 25 mcg | 3.0% | 7,668 | 5,153 | $426K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.9% | 15,046 | 10,203 | $406K |
57 more codes
| J0897 | Injection, denosumab, 1 mg | 2.7% | 770 | $373K |
| J9202 | Goserelin acetate implant, per 3.6 mg | 2.5% | 1,229 | $353K |
| J9306 | Injection, pertuzumab, 1 mg | 2.4% | 120 | $338K |
| 99205 | Prolong outpt/office vis | 2.0% | 6,146 | $284K |
| 36415 | Collection of venous blood by venipuncture | 1.8% | 11,465 | $246K |
| Q5114 | Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg | 1.7% | 147 | $239K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.5% | 7,095 | $206K |
| Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | 1.3% | 133 | $186K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 1.2% | 21,810 | $174K |
| Q5129 | Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | 1.1% | 166 | $149K |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | <1% | 220 | $128K |
| 96417 | <1% | 5,330 | $123K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 684 | $121K |
| J9171 | Injection, docetaxel, 1 mg | <1% | 1,066 | $119K |
| 99223 | Prolong inpt eval add15 m | <1% | 2,840 | $113K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 14,827 | $93K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 5,923 | $85K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 17,514 | $84K |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | <1% | 383 | $79K |
| J9070 | Cyclophosphamide, 100 mg | <1% | 160 | $65K |
| 80053 | Comprehensive metabolic panel | <1% | 2,972 | $65K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,069 | $63K |
| 96127 | <1% | 17,783 | $61K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,039 | $56K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,136 | $46K |
| 96402 | <1% | 2,832 | $32K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,981 | $31K |
| 96415 | <1% | 2,625 | $30K | |
| J1437 | Injection, ferric derisomaltose, 10 mg | <1% | 65 | $29K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,812 | $29K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 4,366 | $24K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 686 | $20K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 348 | $18K |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 551 | $13K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,350 | $11K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 977 | $9K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 379 | $8K |
| J1566 | Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg | <1% | 16 | $6K |
| J1442 | Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | <1% | 37 | $6K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 2,669 | $3K |
| J9045 | Injection, carboplatin, 50 mg | <1% | 186 | $3K |
| 96411 | <1% | 210 | $2K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 14 | $1K |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 27 | $1K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 13 | $1K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 731 | $337.59 |
| J9395 | Injection, fulvestrant, 25 mg | <1% | 26 | $320.96 |
| 80076 | <1% | 702 | $287.87 | |
| J9000 | Injection, doxorubicin hydrochloride, 10 mg | <1% | 13 | $275.94 |
| 82728 | <1% | 253 | $218.93 | |
| 96401 | <1% | 23 | $94.74 | |
| 82746 | <1% | 112 | $83.84 | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 16 | $46.00 |
| 82607 | <1% | 34 | $41.50 | |
| 96523 | <1% | 26 | $35.09 | |
| 85379 | <1% | 13 | $22.75 | |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation agreement | 0% | 355 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBAGDASARIAN, BORIS (AUTHORIZED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Los Angeles Hematology-Oncology Medical Group | Glendale, CA | $725.69 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.